DOI: 10.4244/EIJ-E-21-00008

Breaking down the barriers in the management of INOCA: how can we do better in the diagnosis of coronary vasomotor disorders?

Vijay Kunadian1,2, MBBS, MD, FRCP; Daniell Edward Raharjo1,3, MBBS, MRes

In the mitigation of ischaemic heart disease as the world’s greatest contributor to mortality, coronary vasomotor disorders (CVaD) remain frequently overlooked in their diagnosis and management. CVaD, consisting of vasospastic angina (VSA) and microvascular angina (MVA) as endotypes, are commonly found in 7-50% of patients with ischaemia with non-obstructive coronary arteries (INOCA), with a three-year major adverse cardiovascular event (MACE; death or myocardial infarction [MI]) rate of ~5-37%. The European Association of Percutaneous Cardiovascular Interventions (EAPCI) consensus document helped raise awareness of INOCA among clinicians and patients worldwide1. However, despite highlighting the critical role of coronary functional testing (CFT) in routine clinical practice, its application is still far from optimised. In this issue, Feenstra et al conducted a comprehensive review of various CFT diagnostic protocols for CVaD2.

Discrepancies in coronary vasomotor function testing protocols

Feenstra et al noted significant variations in study protocols, including the aspect of vascular domains tested, the method of testing, and the techniques utilised to measure coronary function to determine the presence of CVaD (Figure 1).

Figure 1. Current challenges in coronary functional testing to diagnose coronary vasomotor disorders.

Firstly, the vascular domain being assessed may be differentiated into the epicardial vessels (>500 µm in diameter) and the microvasculature (<500 µm) which includes pre-arterioles, arterioles, capillaries, and venules. The authors emphasise the importance of distinguishing these domains, as diagnostic and treatment modalities require different approaches. Indeed, the Coronary Vasomotor Disorders International Study (COVADIS) group define VSA as angina precipitated by spasms of the epicardial domain, whereas MVA is defined as that caused by dysfunction in the microcirculation.

Secondly, how CFT is done also varies between protocols in terms of the agent used, injection time, dose, artery being catheterised, order of testing, and techniques for measurement. Acetylcholine (ACh) is the most commonly used pharmacological agent among the reviewed protocols for vasoconstriction assessment and for testing endothelial-dependent vasodilation when injected in low doses. The use of ACh is preferred over its substitute, ergonovine, as the latter is more likely to cause extended vasospasm. ACh protocols range from 20-second injections of incremental ACh doses up to 200 µg to trigger spasms, to suggesting 3-minute infusions of up to 44 µg of ACh—the latter mostly focusing on endothelial-dependent changes. Some protocols combine both by giving slow, low-dose infusions followed by rapid, high-dose boluses of ACh to gain insight into both endothelial-dependent changes and vasospasticity. The matter of dose is especially important as it will affect sensitivity and specificity—essentially a balancing act to find the right dose to best identify dysfunction without compromising on false positives.

A majority of protocols measure the entire left circulation by injecting the agent into the left main stem while some prefer to inject specifically into the left anterior descending artery to avoid spasm affecting a large area of the heart. In an effort to avoid complications affecting the atrioventricular node, most protocols also avoid testing the right coronary artery unless indicated. Although most protocols agree that vasoactive medications should be stopped before CFT, the range may vary from 24-72 hours prior to testing. Despite discrepancies in testing methods, the six protocols reviewed still agree upon a common diagnostic criteria for types of CVaD. For positive findings of epicardial vasoconstriction with ACh, all protocols follow the COVADIS definitions involving appearance of chest pain, ischaemic electrocardiogram (ECG) changes, and >90% constriction of vessels on angiography.

But why is there reluctance in vasomotor testing?

The use of ACh for the diagnosis of VSA and MVA is recommended by the 2019 European Society of Cardiology Chronic Coronary Syndromes (ESC CCS) clinical practice guidelines3, based on its demonstrated safety and efficacy4. There might be reluctance to use CFT due to fear of complications or lack of experience. However, previous studies have suggested that severe side effects such as an abrupt coronary flow obstruction, which can result in cardiac arrhythmias including ventricular fibrillation, occur in the same order of magnitude as described for diagnostic cardiac catheterisation. The most often reported side effect is ACh-induced bradycardia, occurring in 3.2% of cases. This is always transient, providing reassurance to clinicians in the use of ACh. Figure 2 summarises a stepwise algorithm for CFT that may be adopted in the cardiac catheterisation laboratory for the diagnosis of CVaD5. Informed consent should be obtained for unlicensed, parenteral use of ACh and it should only be administered by experienced interventional cardiologists.

Figure 2. Proposed algorithm for CFT to diagnose coronary vasomotor disorder. *some centres administer over 20 seconds. CCB: calcium channel blocker; CFT: coronary functional testing; ECG: electrocardiogram; LCA: left coronary atery; RCA: right coronary artery

Conclusion

Despite being safe, CFT remains far from being optimally applied in clinical settings, which leads to the underdiagnosis and undermanagement of patients with INOCA. Whilst further research is awaited, a coronary vasomotor disorder diagnostic algorithm, based on available studies, can be implemented in cardiac catheterisation laboratories. As long as INOCA remains overlooked, our relentless fight in mitigating cardiovascular disease will stagnate due to the morbidity and mortality arising from this hidden disease.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.


References

Volume 17 Number 15
Feb 18, 2022
Volume 17 Number 15
View full issue


Key metrics

Suggested by Cory

Clinical Research

10.4244/EIJ-D-21-00402 Feb 18, 2022
Principles and pitfalls in coronary vasomotor function testing
Feenstra R et al
free

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free

Editorial

10.4244/EIJ-E-22-00056 Feb 6, 2023
ResETTing the diagnostic utility of exercise tolerance testing for INOCA
Ali ZA and Jeremias A
free

Editorial

10.4244/EIJ-E-22-00033 Oct 21, 2022
Some endotypes of microvascular dysfunction may be more worrisome than others
Maas A and Damman P
free

Original Research

10.4244/EIJ-D-24-00111 Oct 7, 2024
Absolute coronary blood flow across different endotypes of ANOCA
Paradies V et al

10.4244/EIJV14I5A89 Aug 3, 2018
Microvascular disease, what little we know
Appelman Y
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved